Reasons and possible mechanisms for pursuing treatment-free remission in chronic myeloid leukemia
10.3760/cma.j.cn115356-20191208-00242
- VernacularTitle:慢性粒细胞白血病追求无治疗缓解的原因及可能机制
- Author:
Zhongqing ZOU
1
;
Yunfan YANG
;
Li ZHANG
;
Ling PAN
Author Information
1. 四川大学华西医院血液科 610041
- From:
Journal of Leukemia & Lymphoma
2020;29(6):371-374
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 has significantly improved the survival and prognosis of patients with chronic myeloid leukemia (CML). However, long-term treatment with TKI has caused many problems like adverse drug reactions, decreasing the quality of patients' life and increasing financial burden. Therefore, whether CML patients can successfully stop taking TKI after reaching a certain therapeutic standard has become a matter of concern. At present, treatment-free remission (TFR) has already become a new target for CML therapy. Several clinical trials have confirmed the feasibility and safety of TFR in specific patient populations, and TFR is now incorporated into clinical guidelines. This paper reviews the main reasons for CML patients' pursuit of TFR and the possible mechanisms of TFR.
